Salud financiera de hoja de balance de Shandong Xinhua Pharmaceutical
Salud financiera controles de criterios 5/6
Shandong Xinhua Pharmaceutical tiene unos fondos propios totales de CN¥4.7B y una deuda total de CN¥1.4B, lo que sitúa su ratio deuda/fondos propios en 28.8%. Sus activos y pasivos totales son CN¥7.9B y CN¥3.2B respectivamente. Shandong Xinhua Pharmaceutical El EBIT de la empresa es de CN¥559.5M, por lo que su ratio de cobertura de intereses es de 24.4. Su tesorería e inversiones a corto plazo ascienden a CN¥824.3M.
Información clave
28.4%
Ratio deuda-patrimonio
CN¥1.36b
Deuda
| Ratio de cobertura de intereses | 26.6x |
| Efectivo | CN¥918.33m |
| Patrimonio | CN¥4.78b |
| Total pasivo | CN¥3.51b |
| Activos totales | CN¥8.29b |
Actualizaciones recientes sobre salud financiera
Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26
Recent updates
Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
Jan 23Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 05Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years
Jan 18Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?
Dec 29Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?
Dec 14Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26Análisis de la situación financiera
Pasivos a corto plazo: 719Los activos a corto plazo (CN¥3.0B) de la empresa superan a sus pasivos a corto plazo (CN¥2.2B).
Pasivo a largo plazo: 719Los activos a corto plazo (CN¥3.0B) superan a sus pasivos a largo plazo (CN¥1.0B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 719(11.3%) se considera satisfactoria.
Reducción de la deuda: 719 ha pasado de 47.2% a 28.8% en los últimos 5 años.
Cobertura de la deuda: 719's debt is not well covered by operating cash flow (19.5%).
Cobertura de intereses: 719Los pagos de intereses de su deuda están bien cubiertos por el EBIT (24.4x cobertura).